TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026GuruFocus · 1 day ago
TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026Business Wire · 1 day ago
TG Therapeutics Highlights New Clinical Data Across Multiple Sclerosis Portfolio at MSToronto2026Business Wire · 3 days ago
TGTX Stock Rises 60% in 6 Months: Here's What You Should KnowZacks Investment Research · Oct 13, 2026
TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple SclerosisBusiness Wire · Oct 12, 2026
TG Therapeutics Announces Schedule of Data Presentations at MSToronto2026Business Wire · Oct 8, 2026Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 3, 2026 | $0.31 | $0.05 | Miss |
| May 6, 2026 | $0.23 | $0.14 | Miss |
| Feb 26, 2026 | $0.35 | $0.14 | Miss |
| Nov 3, 2025 | $0.24 | $2.43 | Beat |
| Aug 4, 2025 | $0.32 | $0.17 | Miss |
| May 5, 2025 | $0.18 | $0.03 | Miss |